Evogene Ltd. Revenue 2011-2026 | EVGN

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Evogene Ltd.

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
8.51 M	5.64 M	1.68 M	930 K	1.04 M	753 K	1.75 M	3.38 M	6.54 M	11.1 M	14.5 M	17.6 M	17.1 M	14.9 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
17.6 M	753 K	7.53 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
Aptorum Group Limited APM	912 K	$ 0.82	-3.48 %	$ 4.47 M	China
Rigel Pharmaceuticals RIGL	294 M	$ 33.23	-4.03 %	$ 584 M	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Acer Therapeutics ACER	1.26 M	-	2.71 %	$ 14 M	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Apellis Pharmaceuticals APLS	1 B	$ 20.15	-2.68 %	$ 2.54 B	USA
AbCellera Biologics ABCL	75.1 M	$ 3.72	-2.75 %	$ 1.11 B	Canada
Athersys ATHX	5.51 M	-	3.77 %	$ 22.4 M	USA
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
AVEO Pharmaceuticals AVEO	42.3 M	-	-	$ 521 M	USA
Axsome Therapeutics AXSM	638 M	$ 163.7	-1.61 %	$ 8.14 B	USA
BridgeBio Pharma BBIO	502 M	$ 64.66	-1.37 %	$ 12.4 B	USA
BioDelivery Sciences International BDSI	167 M	-	-4.8 %	$ 255 M	USA
Burford Capital Limited BUR	330 M	$ 8.52	-2.46 %	$ 1.39 B	Britain
Adverum Biotechnologies ADVM	1 M	-	-	$ 86.2 M	USA
CymaBay Therapeutics CBAY	31.1 M	-	-	$ 3.45 B	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
Avid Bioservices CDMO	140 M	-	-	$ 789 M	USA
Certara CERT	419 M	$ 7.16	1.49 %	$ 1.15 B	USA
Checkpoint Therapeutics CKPT	41 K	-	-	$ 169 M	USA
Caladrius Biosciences CLBS	1 M	-	-16.75 %	$ 25.8 M	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Clovis Oncology CLVS	149 M	-	-7.23 %	$ 13 M	USA
Acorda Therapeutics ACOR	118 M	-	-24.86 %	$ 820 K	USA
Capricor Therapeutics CAPR	25.2 M	$ 25.91	-3.56 %	$ 694 M	USA
Catalyst Pharmaceuticals CPRX	589 M	$ 24.0	0.5 %	$ 2.93 B	USA
Acasti Pharma ACST	100 M	-	4.01 %	$ 150 M	Canada
Codexis CDXS	59.3 M	$ 0.99	-3.28 %	$ 72.7 M	USA
CTI BioPharma Corp. CTIC	53.9 M	-	-	$ 1.2 B	USA
Cyclacel Pharmaceuticals CYCC	43 K	-	-5.98 %	$ 34.1 M	USA
Cyclacel Pharmaceuticals CYCCP	43 K	-	-4.36 %	$ 27 M	USA
Deciphera Pharmaceuticals DCPH	163 M	-	-	$ 2.18 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Aeterna Zentaris AEZS	9.59 M	-	5.93 %	$ 314 M	Canada
Denali Therapeutics DNLI	331 M	$ 20.02	-4.67 %	$ 3.29 B	USA
AgeX Therapeutics AGE	142 K	-	-10.17 %	$ 12.2 K	USA
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
Eton Pharmaceuticals ETON	31.6 M	$ 17.54	-3.36 %	$ 450 M	USA
Entasis Therapeutics Holdings ETTX	7 M	-	-	$ 105 M	USA
Evofem Biosciences EVFM	18.2 M	-	7.55 %	$ 38.1 M	USA